Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy
Peter G. Miller, Adam S. Sperling, Elliott J. Brea, et al.
Blood Advances (2021) Vol. 5, Iss. 15, pp. 2982-2986
Open Access | Times Cited: 93

Showing 1-25 of 93 citing articles:

Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations
Kai Rejeski, Marion Subklewe, Mahmoud Aljurf, et al.
Blood (2023) Vol. 142, Iss. 10, pp. 865-877
Open Access | Times Cited: 143
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy
Guido Ghilardi, Joseph A. Fraietta, James N. Gerson, et al.
Nature Medicine (2024)
Closed Access | Times Cited: 136
Cytopenia after CAR-T Cell Therapy—A Brief Review of a Complex Problem
Naman Sharma, Patrick M. Reagan, Jane L. Liesveld
Cancers (2022) Vol. 14, Iss. 6, pp. 1501-1501
Open Access | Times Cited: 77
Clonal haematopoiesis and dysregulation of the immune system
Roger Belizaire, Waihay J. Wong, Michelle L. Robinette, et al.
Nature reviews. Immunology (2023) Vol. 23, Iss. 9, pp. 595-610
Closed Access | Times Cited: 69
Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System
Magdi Elsallab, Moataz Ellithi, Matthew A. Lunning, et al.
Blood (2024) Vol. 143, Iss. 20, pp. 2099-2105
Open Access | Times Cited: 67
A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy
David M. Cordas dos Santos, Tobias Tix, Roni Shouval, et al.
Nature Medicine (2024) Vol. 30, Iss. 9, pp. 2667-2678
Open Access | Times Cited: 60
Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management
Kai Rejeski, Michael D. Jain, Nirali N. Shah, et al.
The Lancet Haematology (2024) Vol. 11, Iss. 6, pp. e459-e470
Closed Access | Times Cited: 22
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee
Yi Lin, Lugui Qiu, Saad Z. Usmani, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 8, pp. e374-e387
Closed Access | Times Cited: 19
T cell malignancies after CAR T cell therapy in the DESCAR-T registry
Rémy Duléry, Vincent Guiraud, Sylvain Choquet, et al.
Nature Medicine (2025)
Closed Access | Times Cited: 9
Clonal hematopoiesis: Mutation-specific adaptation to environmental change
Marcus A. Florez, Brandon T. Tran, Trisha K. Wathan, et al.
Cell stem cell (2022) Vol. 29, Iss. 6, pp. 882-904
Open Access | Times Cited: 69
Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma
Neeraj Saini, David M. Swoboda, Uri Greenbaum, et al.
Blood Cancer Discovery (2022) Vol. 3, Iss. 5, pp. 385-393
Open Access | Times Cited: 54
Mechanisms and management of CAR T toxicity
Christopher Ferreri, Manisha Bhutani
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 14
Future perspectives on engineered T cells for cancer
Avery D. Posey, Regina M. Young, Carl H. June
Trends in cancer (2024) Vol. 10, Iss. 8, pp. 687-695
Open Access | Times Cited: 14
Aggressive Lymphoma after CD19 CAR T-Cell Therapy
Guido Kobbe, Monika Brüggemann, Ben‐Niklas Baermann, et al.
New England Journal of Medicine (2024) Vol. 391, Iss. 13, pp. 1217-1226
Closed Access | Times Cited: 12
CHIP Happens: Clonal Hematopoiesis of Indeterminate Potential and Its Relationship to Solid Tumors
Sarah C. Reed, Sarah Croessmann, Ben Ho Park
Clinical Cancer Research (2022) Vol. 29, Iss. 8, pp. 1403-1411
Open Access | Times Cited: 38
Prevalence and variation of CHIP in patients with aggressive lymphomas undergoing CD19-directed CAR T-cell treatment
Raphael Teipel, Frank Kroschinsky, Michael Krämer, et al.
Blood Advances (2022) Vol. 6, Iss. 6, pp. 1941-1946
Open Access | Times Cited: 37
Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for Non-Hodgkin Lymphoma
Hassan B. Alkhateeb, Razan Mohty, Patricia T. Greipp, et al.
Blood Cancer Journal (2022) Vol. 12, Iss. 7
Open Access | Times Cited: 30
Clonal hematopoiesis: Molecular and clinical implications
Yael Kusne, Zhuoer Xie, Mrinal M. Patnaik
Leukemia Research (2022) Vol. 113, pp. 106787-106787
Closed Access | Times Cited: 29
PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy
Peter G. Miller, Adam S. Sperling, Christina Mayerhofer, et al.
Blood (2023) Vol. 142, Iss. 24, pp. 2079-2091
Open Access | Times Cited: 21
Clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated Patients
Victoria Panagiota, Johanna Franziska Kerschbaum, Olaf Penack, et al.
HemaSphere (2023) Vol. 7, Iss. 10, pp. e957-e957
Open Access | Times Cited: 21
Recognizing, defining, and managing CAR-T hematologic toxicities
Kai Rejeski, Marion Subklewe, Frederick L. Locke
Hematology (2023) Vol. 2023, Iss. 1, pp. 198-208
Closed Access | Times Cited: 19
Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines
Guido Ghilardi, Luca Paruzzo, Jakub Svoboda, et al.
Blood Advances (2023) Vol. 8, Iss. 3, pp. 653-666
Open Access | Times Cited: 17
The crossroads of cancer therapies and clonal hematopoiesis
Abhay Singh, Suresh Kumar Balasubramanian
Seminars in Hematology (2024) Vol. 61, Iss. 1, pp. 16-21
Open Access | Times Cited: 8
T-Cell Cancer after CAR T-Cell Therapy
Emily Mitchell, George S. Vassiliou
New England Journal of Medicine (2024) Vol. 390, Iss. 22, pp. 2120-2121
Closed Access | Times Cited: 8
Single-Cell DNA Sequencing Reveals an Evolutionary Pattern of CHIP in Transplant Eligible Multiple Myeloma Patients
Enrica Borsi, Ilaria Vigliotta, Andrea Poletti, et al.
Cells (2024) Vol. 13, Iss. 8, pp. 657-657
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top